IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.

TPS4141Background: Hepatocellular carcinoma (HCC) is a lethal disease with the highest mortality-to-incidence ratio of any solid tumor. The current standard of care for 1L treatment of patients (pts) with locally advanced or metastatic HCC is sorafenib (sor), a multikinase inhibitor. Single-agent treatment involving inhibition of PD-L1/PD-1 immune checkpoint or VEGF has shown modest activity in HCC. Evidence from a Phase I study (Stein ASCO 2018, submitted) in HCC supports a strong scientific rationale for combining atezolizumab (atezo; anti–PD-L1) with bevacizumab (bev; anti-VEGF) to achieve greater clinical benefit. In addition to its anti-angiogenic activity, bev may have immunomodulatory effects in the tumor microenvironment (increased DC maturation, enhanced T-cell infiltration, reduced MDSCs and Tregs in tumors) that can potentially increase the efficacy of atezo in inhibiting PD-L1/PD-1 signaling and restoring anti-tumor T-cell activity. Methods: IMbrave150 (YO40245) is a Phase III, open-label, mul...